Compare Inovio Pharmaceuticals Inc (INO) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs CarMax, Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while CarMax, Inc trades at $52.61 (market cap $7.64B). The key difference: CarMax, Inc is far larger — about 68.1× Inovio Pharmaceuticals Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and CarMax, Inc for 49 Days on average.
| INO | KMX | |
|---|---|---|
Market Cap | $112.19M | $7.64B |
Volume | 3,201,278 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.60 | $64.22 |
52-Week Low | $0.66 | $30.88 |
Typical Hold Time | 43 Days | 49 Days |
Enterprise Value | $83.51M | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
CarMax (KMX) trades at $53.79, up 0.96% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but strong fundamental improvements with Q2 2026 EPS of $1.16 beating estimates by 58%. Revenue grew 19.5% to $7.9 billion in the latest quarter, while the company's Shift into GEAR strategy shows early success. Valuation metrics remain reasonable with P/E of 25.37 and P/S of 0.28, though net margins remain thin at 1.06%.
KMX presents a turnaround story with improving operational execution but faces margin pressure and high debt levels. The consensus price target of $58.89 suggests 9.5% upside potential, though analyst sentiment remains cautious with 62% hold ratings. Key risks include used car market volatility and interest rate sensitivity, while catalysts include continued execution of the growth strategy and potential share buybacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
